Abstract
We read with interest the article by Overwater et al.,1 which showed that sirolimus did not significantly reduce seizure frequency in children with tuberous sclerosis complex (TSC) and intractable epilepsy.1 TSC/mammalian target of rapamycin signaling is involved in regulating cell proliferation, synaptogenesis, and growth of dendrites and axons.2,3 This suggests that any treatment aimed at correcting TSC-related epilepsy would need to be initiated during important developmental time windows.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
